QuidelOrtho Corporation

NasdaqGS QDEL

QuidelOrtho Corporation EBITDA for the Trailing 12 Months (TTM) ending September 29, 2024: USD -1.40 B

QuidelOrtho Corporation EBITDA is USD -1.40 B for the Trailing 12 Months (TTM) ending September 29, 2024, a -306.75% change year over year. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.
  • QuidelOrtho Corporation EBITDA for the Trailing 12 Months (TTM) ending October 01, 2023 was USD 678.90 M, a -52.40% change year over year.
  • QuidelOrtho Corporation EBITDA for the Trailing 12 Months (TTM) ending October 02, 2022 was USD 1.43 B, a 19.08% change year over year.
  • QuidelOrtho Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 1.20 B, a 125.85% change year over year.
  • QuidelOrtho Corporation EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 530.37 M, a 305.56% change year over year.
Key data
Date EBITDA Net Income EPS (Diluted) Shares (Diluted, Weighted)
Market news
Loading...
NasdaqGS: QDEL

QuidelOrtho Corporation

CEO Mr. Brian J. Blaser
IPO Date Feb. 1, 1991
Location United States
Headquarters 9975 Summers Ridge Road
Employees 7,100
Sector Health Care
Industries
Description

QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; and analyzers and amplification systems. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was founded in 1979 and is headquartered in San Diego, California.

Similar companies

BRKR

Bruker Corporation

USD 61.26

-2.69%

PODD

Insulet Corporation

USD 267.04

-0.35%

INSP

Inspire Medical Systems, Inc.

USD 169.99

-3.10%

CNMD

CONMED Corporation

USD 67.79

-2.46%

LIVN

LivaNova PLC

USD 47.63

0.66%

DXCM

DexCom, Inc.

USD 79.17

-0.84%

SIBN

SI-BONE, Inc.

USD 15.70

-3.27%

STE

STERIS plc

USD 207.57

0.10%

MASI

Masimo Corporation

USD 166.09

0.31%

KIDS

OrthoPediatrics Corp.

USD 23.55

-5.80%

NARI

Inari Medical, Inc.

USD 79.30

-0.05%

TNDM

Tandem Diabetes Care, Inc.

USD 35.79

-1.16%

LUNG

Pulmonx Corporation

USD 6.84

-2.98%

PEN

Penumbra, Inc.

USD 252.89

2.41%

GKOS

Glaukos Corporation

USD 147.95

-2.58%

NPCE

NeuroPace, Inc.

USD 11.84

-2.23%

StockViz Staff

January 15, 2025

Any question? Send us an email